Banque Pictet & Cie Sa Novo Cure LTD Transaction History

Banque Pictet & Cie Sa

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$11.13 - $15.78 $1.39 Million - $1.97 Million	124,967 Added 333.25%	162,467 $2.43 Million
Q3 2023 Nov 02, 2023	SELL	$16.15 - $42.35 $336,000 - $881,091	-20,805 Reduced 35.68%	37,500 $605,000
Q2 2023 Aug 04, 2023	BUY	$40.29 - $82.51 $1.05 Million - $2.14 Million	25,985 Added 80.4%	58,305 $2.42 Million
Q1 2023 May 01, 2023	SELL	$56.44 - $118.81 $1.59 Million - $3.34 Million	-28,087 Reduced 46.5%	32,320 $1.94 Million
Q4 2022 Feb 06, 2023	BUY	$63.98 - $85.37 $1.91 Million - $2.54 Million	29,778 Added 97.22%	60,407 $0
Q3 2022 Nov 10, 2022	SELL	$67.99 - $89.57 $3.05 Million - $4.01 Million	-44,797 Reduced 59.39%	30,629 $2.33 Billion
Q2 2022 Aug 08, 2022	BUY	$56.6 - $89.9 $1.33 Million - $2.11 Million	23,503 Added 45.27%	75,426 $5.24 Million
Q1 2022 May 04, 2022	SELL	$60.15 - $84.52 $14.9 Million - $21 Million	-248,049 Reduced 82.69%	51,923 $4.3 Million
Q4 2021 Feb 02, 2022	BUY	$75.08 - $121.99 $22.5 Million - $36.6 Million	299,972 New	299,972 $22.5 Million

263

76.9M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.76B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.